ArticleInternational medical case reports journal2025
Full-Thickness Macular Hole Formation After Intravitreal Faricimab Injection for Polypoidal Choroidal Vasculopathy.
Article in International medical case reports journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To report a case of an Asian man with idiopathic polypoidal choroidal vasculopathy (PCV) who developed a full-thickness macular hole (FTMH) following treatment with intravitreal faricimab, which resolved after vitreoretinal surgery. Patients and Methods: A 63-year-old man with idiopathic PCV was treated with intravitreal faricimab. Although pigment epithelial detachment (PED) decreased, he developed cystoid macular edema with vitreomacular traction (VMT), which progressed to a FTMH. Results: Pars plana vitrectomy and internal limiting membrane peeling successfully treated the FTMH. One year after the procedure, the macular hole remains closed, and the PCV was inactive. Conclusion: Various mechanisms may have contributed to the exacerbation of the preexisting VMT and PED, which finally resulted in the development of a FTMH. Careful attention should be paid to changes in the vitreomacular interface and posterior vitreous detachment before performing intravitreal anti-vascular endothelial growth factor treatment. Nevertheless, FTMHs can be successfully treated with prompt vitreoretinal surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.